Strides Pharma Slips After USFDA Issues Four Observations

The stock of Strides Pharma Science fell 1.02 percent to 928.85 when its step-down subsidiary, Strides Pharma Inc. USA (SPI), had four observations by the US Food and Drug Administration (USFDA) after a routine inspection.

In an exchange filing, the company reported that the present Good Manufacturing Practices (cGMP) inspection was performed by the USFDA at its formulations manufacturing plant in Chestnut Ridge, New York, either 17 December to 23 December 2025. This is because, by the end of the inspection, the regulator gave four observations in a Form 483.

To explain the development, Strides Pharma said that the observations are procedural because they are not likely to affect the supply of its commercial products. The company also indicated that SPI will provide a detailed response to the USFDA within the specified period, and it is certain that it will respond to all the observations to the satisfaction of the regulator.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

The company also indicated that it would update the stock exchanges on all material developments in the same manner. It officially announced its disclosure on 24 December 2025, when the market is closed.

Strides Pharma Science is a multinational pharmaceutical firm that is based in Bengaluru and has a major interest in the production and development of niche and technologically challenging pharmaceutical products in regulated and emerging markets.

The observers in the industry observe that timely and proper implementation of the regulatory observation is critical in sustaining supply reliability and long-term credibility in the US generics market.